Interleukin-4Ralpha Blockade by Dupilumab Decreases Staphylococcus Aureus Colonization and Increases Microbial Diversity in Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)
Latest Information Update: 04 Dec 2023
Price :
$35 *
At a glance
- Drugs Dupilumab (Primary)
- Indications Nasal polyps; Rhinosinusitis
- Focus Therapeutic Use
- 06 Mar 2023 Status changed from not yet recruiting to recruiting.
- 20 Jun 2022 Planned primary completion date changed from 31 Dec 2023 to 30 Jun 2024.
- 20 Jun 2022 Planned initiation date changed from 30 May 2022 to 1 Jul 2022.